Erdem Gürel

Erdem Gürel

Auto-generated profile, based on publicly available information

Erdem Gürel

Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Clinical Nutrition
Verified
Journal Article
Closed access
MAMustafa Altinkaynak
Mustafa Altinkaynak
EGErdem Gurel
Erdem Gurel
MÖMeryem Merve Ören
Meryem Merve Ören
CKCihan Kilic
Cihan Kilic
MKMehmet AKİF Karan
Mehmet AKİF Karan
Gülistan BahatGülistan Bahat
Gülistan Bahat

3 April 2024 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ŞMŞafak Mi̇rİoĞlu
Şafak Mi̇rİoĞlu
SÇSuzan ÇINAR
Suzan ÇINAR
ÖUÖmer Uludağ
Ömer Uludağ
EGErdem Gürel
Erdem Gürel
SVSibel Varelci̇
Sibel Varelci̇
BEBahar Artim Esen
Bahar Artim Esen
Background/aim: In this prospective study, we aimed to investigate the association of serum (s) and urine (u) IP-10, galectin-9, and SIGLEC-1 with disease activity in patients with systemic lupus erythematosus (SLE).Materials and methods: Sixty-three patients with active SLE (31 renal, 32 extrarenal) were included. Thirty patients with inactive SLE (15 renal, 15 extrarenal), 17 with renal active AAV, and 32 healthy volunteers were selected as control groups. Serum and urine IP-10, galectin-9, and SIGLEC-1 were tested using ELISA.Results: Levels of sIP-10 (p = 0.046), uIP-10 (p < 0.001), sGalectin-9 (p = 0.03), and uSIGLEC-1 (p = 0.006) were significantly higher in active SLE group compared to the inactive SLE; however, no differences were detected in the comparison of uGalectin-9 (p = 0.18) and sSIGLEC-1 (p = 0.69) between two groups. None of the biomarkers discriminated patients with active renal SLE from active extrarenal SLE. ROC analyses revealed an AUC of 0.63 (0.52–0.73) for sIP-10, 0.78 (0.68–0.86) for uIP-10, 0.64 (0.53–0.74) for sGalectin-9, and 0.68 (0.57–0.77) for uSIGLEC-1 in discriminating disease activity in SLE, which did not outperform C3 (0.75, 0.64–0.84) and C4 (0.72, 0.61–0.82). sIP-10 (p = 0.001), uIP-10 (p = 0.042), and uGalectin-9 (p = 0.009) were significantly increased in patients with active renal SLE compared to active renal AAV. sGalectin-9 (p < 0.001) and sIP-10 levels (p = 0.06) were decreased after 8 (5–22.5) months of treatment.Conclusion: sIP-10, uIP-10, sGalectin-9, and uSIGLEC-1 reflect global disease activity in SLE but do not outperform C3 and C4. sIP-10 and uIP-10 may be specific for active SLE compared to active AAV. sIP-10 and sGalectin-9 might be valuable in monitoring response after treatment.

20 October 2025 in bioRxiv
Verified
Preprint
Open access
AGAmalie Grenov
Amalie Grenov
JYJongwon Yoon
Jongwon Yoon
DSDaniel M. Snell
Daniel M. Snell
AMAnna Mikolajczak
Anna Mikolajczak
HWHao Wang
Hao Wang
CVCarola G. Vinuesa
Carola G. Vinuesa
Summary: Anti-CD19 chimeric antigen receptor (CAR)-T therapy induces profound remissions in lupus by depleting B cells, challenging the longstanding view that treatment-resistant disease is sustained by long-lived plasma cells. Additionally, emerging relapses highlight the need to understand how pathogenic autoantibodies arise. Using molecular antibody tagging in mice with human monogenic lupus variants, we reveal that autoantibody-producing cell cohorts are long-lived but plasma cells are short-lived, requiring continuous replenishment from proliferating precursors. The spleen acts as a major plasma cell reservoir, with perivascular localization conserved in mice and lupus patients. Relapse after anti-CD19 CAR-T occurred through newly-generated B cells rather than treatment-resistant clones. Plasma cell depletion by anti-BCMA CAR-T failed to eliminate some precursors that become autoantibody-secreting. These findings demonstrate that continuous B cell-to-plasma cell differentiation, not intrinsic plasma cell longevity, sustains pathogenic antibody responses in lupus, supporting a potential benefit of adjunctive therapies after CAR-T, particularly in genetically predisposed patients.

1 July 2026 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
EGErdem Gürel
Erdem Gürel
SÇSuzan Çinar
Suzan Çinar
ÖHÖzge Hürdogan
Özge Hürdogan
YÖYasemin Özlük
Yasemin Özlük
GKGamze Kemeç
Gamze Kemeç
BABahar Artim-Esen
Bahar Artim-Esen
Objectives: CD163 is a macrophage-associated scavenger receptor shed during inflammatory activation, resulting in measurable soluble CD163 in serum (s) and urine (u). Elevated levels have been reported in inflammatory and immune-mediated conditions, including lupus nephritis (LN). This study aimed to investigate the relationship between soluble CD163 levels and intrarenal CD163 expression, evaluating their association with disease activity and treatment response in LN. Methods: Forty-five patients with systemic lupus erythematosus (SLE) were included (20 active LN, 10 inactive LN, 15 active extra-renal SLE), together with 20 matched healthy controls. Serum and urine samples were collected at baseline alongside renal biopsy in active LN; 6-month follow-up samples were available for 12 active LN patients. CD163 was measured by ELISA; urinary CD163 was normalised to spot urine creatinine. Renal biopsies from 20 active LN patients were evaluated for CD163+ macrophage density. Results: uCD163 was higher in active LN (a renal Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) flare (UPCR ≥0.5 g/g) with biopsy-proven active lesions) than in inactive LN and active extra-renal SLE (both p<0.001), discriminating active from inactive LN (area under the curve (AUC) 0.97) and from extra-renal SLE (AUC 0.89). uCD163 correlated with the National Institutes of Health activity and chronicity indices activity index (ρ=0.55, p=0.016) and with glomerular CD163+ macrophage density (the number of CD163+ macrophages per glomerulus quantified by immunohistochemistry; ρ=0.65, p=0.006), but not with chronicity. Glomerular CD163+ macrophage density also correlated with sCD163 (ρ=0.60, p=0.01) and uCD163 (ρ=0.63, p=0.009). After 6-month induction, uCD163 fell from 7.41 to 1.55 ng/mg (p<0.001). Conclusion: uCD163 distinguishes active LN from inactive renal and extra-renal disease and tracks treatment response. The association with intrarenal CD163+ macrophages supports its biological relevance as a non-invasive marker of renal inflammation, complementary to histopathology when repeat biopsy is not feasible. These findings support uCD163 as a candidate non-invasive tool for identifying active LN and monitoring treatment response in SLE, warranting validation in larger prospective cohorts.